Epstein AL - Search Results

1

Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer.

Chen S, Yu L, Jiang C, Zhao Y, Sun D, Li S, Liao G, Chen Y, Fu Q, Tao Q, Ye D, Hu P, Khawli LA, Taylor CR, Epstein AL, Ju DW. Chen S, et al. Among authors: epstein al. J Clin Oncol. 2005 Mar 1;23(7):1538-47. doi: 10.1200/JCO.2005.06.108. J Clin Oncol. 2005. PMID: 15735129

2

Immunogenicity of Iodine 131 chimeric tumor necrosis therapy monoclonal antibody in advanced lung cancer patients.

Wang H, Cao C, Li B, Chen S, Yin J, Shi J, Ye D, Tao Q, Hu P, Epstein A, Ju D. Wang H, et al. Cancer Immunol Immunother. 2008 May;57(5):677-84. doi: 10.1007/s00262-007-0406-0. Epub 2007 Oct 13. Cancer Immunol Immunother. 2008. PMID: 17934732 Free PMC article. Clinical Trial.

3

Tumor targeting properties of indium-111 labeled genetically engineered Fab' and F(ab')2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody.

Khawli LA, Alauddin MM, Hu P, Epstein AL. Khawli LA, et al. Among authors: epstein al. Cancer Biother Radiopharm. 2003 Dec;18(6):931-40. doi: 10.1089/108497803322702897. Cancer Biother Radiopharm. 2003. PMID: 14969605

4

131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer.

Yu L, Ju DW, Chen W, Li T, Xu Z, Jiang C, Chen S, Tao Q, Ye D, Hu P, Khawli LA, Taylor CR, Epstein AL. Yu L, et al. Among authors: epstein al. Cancer Biother Radiopharm. 2006 Feb;21(1):5-14. doi: 10.1089/cbr.2006.21.5. Cancer Biother Radiopharm. 2006. PMID: 16480326 Clinical Trial.

5

Tumor necrosis treatment of ME-180 human cervical carcinoma model with 131I-labeled TNT-1 monoclonal antibody.

Chen FM, Taylor CR, Epstein AL. Chen FM, et al. Among authors: epstein al. Cancer Res. 1989 Aug 15;49(16):4578-85. Cancer Res. 1989. PMID: 2743341

6

Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin.

Khawli LA, Mizokami MM, Sharifi J, Hu P, Epstein AL. Khawli LA, et al. Among authors: epstein al. Cancer Biother Radiopharm. 2002 Aug;17(4):359-70. doi: 10.1089/108497802760363150. Cancer Biother Radiopharm. 2002. PMID: 12396700

7

Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).

Biela BH, Khawli LA, Hu P, Epstein AL. Biela BH, et al. Among authors: epstein al. Cancer Biother Radiopharm. 2003 Jun;18(3):339-53. doi: 10.1089/108497803322285099. Cancer Biother Radiopharm. 2003. PMID: 12954121

8

NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy.

Khawli LA, Hu P, Epstein AL. Khawli LA, et al. Among authors: epstein al. Clin Cancer Res. 2005 Apr 15;11(8):3084-93. doi: 10.1158/1078-0432.CCR-04-2310. Clin Cancer Res. 2005. PMID: 15837764

9

Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas.

Zhang N, Khawli LA, Hu P, Epstein AL. Zhang N, et al. Among authors: epstein al. Clin Cancer Res. 2005 Aug 15;11(16):5971-80. doi: 10.1158/1078-0432.CCR-05-0554. Clin Cancer Res. 2005. PMID: 16115941

10

Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.

Liu A, Hu P, Khawli LA, Epstein AL. Liu A, et al. Among authors: epstein al. Clin Cancer Res. 2005 Dec 1;11(23):8492-502. doi: 10.1158/1078-0432.CCR-05-1411. Clin Cancer Res. 2005. PMID: 16322313

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

293 results

Search Page

Filters